Florida Just Sued the World's Biggest Vaccine Maker. It's Personal.

Third, Florida argues the whole thing adds up to a wide-ranging deceptive marketing campaign that violated state consumer protection law.

Now, some important context. Myocarditis and pericarditis are recognized rare side effects of mRNA COVID vaccines. The FDA has required labeling about them since 2021. Current Pfizer labeling explicitly highlights these risks, notes they occur most often in younger males after later doses, and does not claim the vaccine prevents all infection. On the pregnancy question, a 2023 meta-analysis found no statistically significant increase in miscarriage risk, though the certainty of that finding was rated low.

So was Pfizer hiding things, or was the science evolving in real time while a massive public health campaign tried to keep up? That's exactly what this case will have to sort out.

The Price Tag Could Be Enormous

Florida isn't just asking Pfizer to stop. The state wants civil penalties of $10,000 per violation, with that number jumping to $15,000 when seniors or disabled people were harmed. It's also seeking disgorgement of profits (meaning Pfizer would have to hand back the money it made) and a permanent injunction to stop the alleged conduct.

Do the math on "per violation" in a state with 23 million people and a massive senior population. Even a fraction of those claims could produce a staggering figure.

Pfizer's response? The company says the case "has no merit" and that its vaccine claims were "accurate and science-based." They've promised to fight it in court.

Meet the Man Behind the Suit

James Uthmeier isn't your typical Attorney General. He was appointed by Governor Ron DeSantis in February 2025 after serving as DeSantis's chief of staff and general counsel. A Georgetown Law grad who previously worked at Jones Day and the U.S. Department of Commerce, Uthmeier has taken an aggressive, culture-war posture in his new role.

Since taking office, he's subpoenaed Anthony Fauci, threatened to pull school vouchers from Catholic schools tied to vaccine requirements, and now sued the world's largest vaccine maker. Bloomberg has described his approach as that of a "culture-war prosecutor." Whether you see him as a consumer champion or a political opportunist probably depends on your priors.

Why This Case Matters Beyond Florida

This lawsuit sits at a fascinating intersection of state power and federal protection.

Vaccine makers have historically been shielded by the PREP Act, a federal law that grants broad liability protection for products used during public health emergencies. Courts have consistently treated COVID-19 vaccines as "covered countermeasures" under this law, making it extremely hard for individuals to sue over injuries. The federal compensation system for vaccine injuries, called the CICP, tells the story: out of 4,111 claims resolved as of April 2025, only 67 were found eligible for compensation. That's a success rate of about 1.6%.

But Florida's case doesn't follow the injury playbook. By framing this as a consumer fraud case about marketing, not a product liability case about injury, Uthmeier is trying to thread the needle around federal protections. It's clever.

If Florida succeeds (or even survives early motions to dismiss), it could create a blueprint for other states to go after vaccine makers without running into the federal immunity wall. That would fundamentally change how pharmaceutical companies communicate about vaccines during a crisis.

The Bigger Picture

This case captures something broader happening in America right now. COVID-19 vaccines saved millions of lives, but the speed at which they were developed, authorized, and marketed left gaps; gaps in communication, gaps in transparency, and gaps in trust.

Whether Pfizer actually deceived consumers or simply communicated imperfectly during an unprecedented pandemic is a genuinely hard legal question. The answer won't come from political commentary or social media debates. It'll come from a courtroom in St. Lucie County, Florida.

And whatever that courtroom decides, every pharma company in America will be watching. Because if a state can successfully sue over how a vaccine was sold rather than how it was made, the rules of the game change for everyone.

Bayer Just Bet $2.2 Billion That Ohio Is the Future of Pharma

Bayer is pouring $2.2 billion into its first-ever North American pharma manufacturing campus in Ohio. The move signals the German giant's biggest bet yet on U.S.-made drugs, but the factory won't produce a single pill until 2031.